Millendo Therapeutics Appoints New Independent Board Member And Names Chairperson Of The Board

ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc., a company developing novel therapies for endocrine diseases caused by hormone dysregulation, today announced the appointment of James Hindman as an independent board member and chairperson of its audit committee. In addition, Millendo has appointed current board member and Partner of New Enterprise Associates, Inc., Carol Gallagher, Pharm.D., as Chairperson of the Board.